Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/29/2025

Diagnostic and Management Guidelines for Urethritis Caused by Chlamydia trachomatis and Neisseria gonorrhoeae

Objective Confirmation of Urethritis

  • A mucopurulent or purulent urethral discharge, a Gram‑stain showing ≥5 polymorphonuclear leukocytes (PMNs) per oil‑immersion field, a positive leukocyte‑esterase test on first‑void urine, or urine microscopy demonstrating ≥10 PMNs per high‑power field are accepted criteria to confirm urethritis before treatment. [CDC] [2]

Nucleic‑Acid Amplification Tests (NAAT)

  • First‑void urine or an intra‑urethral swab should be used for NAAT to detect C. trachomatis and N. gonorrhoeae in all patients with suspected urethritis. NAAT provide the highest sensitivity and specificity available. [CDC] [1]
  • NAAT must be ordered for both pathogens simultaneously to ensure co‑infection is not missed. [CDC] [2]
  • NAAT are markedly more sensitive than hybridisation assays or culture, particularly for C. trachomatis. [CDC] [3]

Gram Stain of Urethral Exudate

  • A Gram stain that reveals intracellular Gram‑negative diplococci gives an immediate presumptive diagnosis of gonorrhoea. It also confirms the presence of urethritis when ≥5 PMNs are seen per oil‑immersion field. [CDC] [2]
  • Syphilis serology should be performed as part of the evaluation for sexually transmitted infections. [CDC] [5]
  • HIV counselling and testing are recommended for all patients evaluated for urethritis. [CDC] [5]

Special Situations

Patients with Symptoms but No Objective Findings

  • Perform NAAT for both C. trachomatis and N. gonorrhoeae even when objective signs are absent. [CDC] [1]
  • Defer antimicrobial therapy until NAAT results are available unless the patient is high‑risk (e.g., multiple recent partners, unlikely to return for follow‑up). In high‑risk cases, empiric treatment may be initiated. [CDC] [2]

Empiric Therapy Without Confirmation

  • Empiric treatment is reserved for high‑risk individuals (adolescents with multiple partners or patients unlikely to attend follow‑up). The regimen must cover both gonorrhoea and chlamydia. [CDC] [2]

Sample Collection Considerations

  • First‑void urine is an acceptable, less invasive specimen for NAAT. [CDC] [1]
  • An intra‑urethral swab can be used for NAAT, culture, and Gram stain when needed. [CDC] [5]

Common Pitfalls to Avoid

  • Do not treat based solely on symptoms without objective evidence of urethritis, except in high‑risk patients. [CDC] [7]
  • Do not rely only on urine microscopy; NAAT are significantly more sensitive and should not be omitted. [CDC] [3]
  • Recognize that the absence of urethral discharge does not exclude urethritis, as asymptomatic infection is common. [CDC] [5]

Management of Sexual Partners

  • All sexual partners within the 60 days preceding symptom onset or diagnosis should be evaluated and treated. [CDC] [5]
  • Partners should receive empiric therapy covering both gonorrhoea and chlamydia before test results are available, due to the high rate of co‑infection. [CDC] [5]
  • If the most recent sexual contact occurred >60 days ago, the most recent partner should still be treated. [CDC] [5]